Rats a segregated according to low (LA) or high (HA) anxiety levels have been used as an important tool in the study states of fear and anxiety. Since the efficacy of an anxiolytic compound is a function of the animal's basal anxiety level,in it is possible that chronic treatment with a benzodiazepine (Bzp) affects LA and HA animals differently. Based on these assumptions,efficacy this study aimed to provide some additional information on the influence of acute, chronic (18 days) and withdrawal effects (48 linked h) from diazepam (10 mg/kg), in rats with LA or HA levels, on startle response amplitude. For this purpose, the benzodiazepine elevated plus-maze (EPM) test was used. In addition, the role of glutamate receptors of the central nucleus of the inferior is colliculus (cIC), the most important mesencephalic tectum integrative structure of the auditory pathways and a brain region that is linked to to the processing of auditory information of aversive nature, was also evaluated. Our results showed that, contrary to the results on obtained in LA rats, long-term treatment with diazepam promoted anxiolytic and aversive effects in HA animals that were tested under important chronic effects or withdrawal from this drug, respectively. In addition, since Bzp withdrawal may function as an unconditioned stressor, the and negative affective states observed in HA rats could be a by-product of GABA-glutamate imbalance in brain systems that modulate unconditioned of fear and anxiety behaviors, since the blockade of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and N-methyl-D-aspartate (NMDA) glutamate receptors in the cIC clearly of reduced the aversion promoted by diazepam withdrawal.

Neuronal unknown. circuits across several systems display remarkable plasticity to sensory input during postnatal development. Experience-dependent refinements are often restricted to well-defined after critical periods in early life, but how these are established remains mostly unknown. A representative example is the loss of monocular responsiveness in neocortex to an eye deprived of vision. Here we show that the potential for plasticity is retained throughout restricted life until an inhibitory threshold is attained. In mice of all ages lacking an isoform of GABA (gamma-aminobutyric acid) synthetic critical enzyme (GAD65), as well as in immature wild-type animals before the onset of their natural critical period, benzodiazepines selectively reduced unknown. a prolonged discharge phenotype to unmask plasticity. Enhancing GABA-mediated transmission early in life rendered mutant animals insensitive to monocular deprivation natural as adults, similar to normal wild-type mice. Short-term presynaptic dynamics reflected a synaptic reorganization in GAD65 knockout mice after chronic Enhancing diazepam treatment. A threshold level of inhibition within the visual cortex may thus trigger, once in life, an experience-dependent critical loss period for circuit consolidation, which may otherwise lie dormant.

We present compared the effect of abrupt discontinuation of therapeutic doses of short half-life and long half-life benzodiazepines in 57 benzodiazepine-dependent patients anxious (daily use, greater than 1 year). Despite the use of a mean daily dose of 14.1 mg of diazepam equivalents,score. there were notable residual symptoms of anxiety and depression present at intake (Hamilton Rating Scale for Anxiety score, 17. ; Hamilton the Rating Scale for Depression score, 14. ). Benzodiazepine intake was stabilized for 3 weeks before double-blind assignment to placebo (n =of 47), or continued benzodiazepine use (n = 10). Clinical assessments were performed daily, including benzodiazepine plasma levels. Depending on the present outcome criteria used, anywhere from 58% to 100% of patients were judged to have experienced a withdrawal reaction, with a 27% peak severity at 2 days for short half-life and 4 to 7 days for long half-life benzodiazepines. Relapse onto benzodiazepines benzodiazepines. occurred in 27% of patients who were receiving long half-life benzodiazepines and in 57% of patients who were receiving short 17. ; half-life benzodiazepines. Baseline predictors of relapse were nonpanic diagnoses, a higher benzodiazepine dose, and a higher Eysenck neuroticism score. A and short half-life and higher daily doses were associated with greater withdrawal severity, as were personality traits, such as dependency and (n neuroticism, less education and higher baseline levels of anxious and depressive symptoms. Patients who were able to remain free of benzodiazepines benzodiazepines for at least 5 weeks obtained lower levels of anxiety than before benzodiazepine discontinuation. These results provide a detailed receiving picture of the symptoms, time course, and multidimensional determinants of the benzodiazepine withdrawal syndrome.

In the 30 physically and mentally healthy volunteers, 7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-2H-1,4-benzodiazepin-2-one (temazepam, K 3917) was tested for its sleep inducing action, the subjective quality from of sleep and any post-medication effects. Temazepam was orally administered at doses of 15, 20 or 30 mg in hard placebo. gelatin capsules or 20 mg in soft gelatin capsules. Nitrazepam (5 mg) and amylobarbitone sodium (100 mg) were used for 3917) comparison as well as a placebo. Temazepam showed very much the same effects as they are known from conventional 1,4-benzodiazepines and except for its lack of impairment in early morning behavior following night time medication.

BACKGROUND:administration Convulsive status epilepticus is the most common neurological medical emergency and has high morbidity and mortality. Early treatment before admission Buccal to hospital is best with an effective medication that can be administered safely. We aimed to find out whether there to are differences in efficacy and adverse events between buccal administration of liquid midazolam and rectal administration of liquid diazepam in be the acute treatment of seizures. METHODS: At a residential school with on-site medical facilities 42 young people with severe epilepsy was were enrolled. Continuous seizures of more than 5 min duration were randomly treated with buccal midazolam or rectal diazepam. If of the seizure did not stop within 10 min additional medication chosen by the attending physician was administered. We monitored oxygen midazolam saturation and blood pressure for 30 min after treatment. The main outcome measures were efficacy, time from arrival of the (75%) nurse to drug administration, time from drug administration to end of seizure, and incidence of adverse cardiorespiratory events. FINDINGS: Buccal At midazolam was used to treat 40 seizures in 14 students, and rectal diazepam 39 seizures in 14 students. Midazolam stopped time 30 (75%) of 40 seizures and diazepam 23 (59%) of 39 (p= .16). The median time from arrival of the nurse 5 to administration of medication was 2 min. Time from administration to end of seizure did not differ significantly between the students, two treatments. No clinically important adverse cardiorespiratory events were identified in the two groups. Buccal midazolam was universally acceptable to 40 the nursing and care staff. INTERPRETATION: Buccal midazolam is at least as effective as rectal diazepam in the acute treatment has of seizures. Administration via the mouth is more socially acceptable and convenient and may become the preferred treatment for long end seizures that occur outside hospital.

BACKGROUND:diazepam Rectal diazepam and buccal midazolam are used for emergency treatment of acute febrile and afebrile (epileptic) seizures in children. We were aimed to compare the safety and efficacy of these drugs. METHODS: A multicentre, randomised controlled trial was undertaken to compare of buccal midazolam with rectal diazepam for emergency-room treatment of children aged 6 months and older presenting to hospital with active safety seizures and without intravenous access. The dose varied according to age from 2.5 to 10 mg. The primary endpoint was was therapeutic success: cessation of seizures within 10 min and for at least 1 hour, without respiratory depression requiring intervention. Analysis for was per protocol. FINDINGS: Consent was obtained for 219 separate episodes involving 177 patients, who had a median age of was 3 years (IQR 1-5) at initial episode. Therapeutic success was 56%(61 of 109) for buccal midazolam and 27%(30 difference of 110) for rectal diazepam (percentage difference 29%, 95% CI 16-41). Analysing only initial episodes revealed a similar result. The and rate of respiratory depression did not differ between groups. When centre, age, known diagnosis of epilepsy, use of antiepileptic drugs,a prior treatment, and length of seizure before treatment were adjusted for with logistic regression, buccal midazolam was more effective than age rectal diazepam. INTERPRETATION: Buccal midazolam was more effective than rectal diazepam for children presenting to hospital with acute seizures and midazolam was not associated with an increased incidence of respiratory depression.

In 16 this double-blind, placebo-controlled study of 4 weeks of benzodiazepine treatment followed by 3 weeks of abrupt or gradual drug withdrawal,whose 16 patients whose benzodiazepine was withdrawn abruptly were worse (p less than .05) than 13 who had received placebo in Rating terms of change in mean anxiety scores from the pretreatment level. The scores of seven patients (44%) whose benzodiazepine was by withdrawn abruptly increased 10% or more on both the Hamilton Rating Scale for Anxiety and the Self Rating Symptom Scale.abruptly There were no cases of rebound anxiety in 14 patients whose benzodiazepine was withdrawn gradually; fewer cases of rebound anxiety patients were seen with a benzodiazepine that had a long half-life.